[1]周 钧a,汪庭军b,唐 珍a.甲状腺乳头状癌患者血清EGR1/2 mRNA 水平检测在临床早期实验诊断中的价值研究[J].现代检验医学杂志,2023,38(05):93-98.[doi:10.3969/j.issn.1671-7414.2023.05.018]
　ZHOU Juna,WANG Tingjunb,TANG Zhena.Value of Serum EGR1/2 mRNA Detection in Early Clinical Diagnosis of Papillary Thyroid Carcinoma[J].Journal of Modern Laboratory Medicine,2023,38(05):93-98.[doi:10.3969/j.issn.1671-7414.2023.05.018]
点击复制

甲状腺乳头状癌患者血清EGR1/2 mRNA 水平检测在临床早期实验诊断中的价值研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第38卷
期数:
2023年05期
页码:
93-98
栏目:
论著
出版日期:
2023-09-15

文章信息/Info

Title:
Value of Serum EGR1/2 mRNA Detection in Early Clinical Diagnosis of Papillary Thyroid Carcinoma
文章编号:
1671-7414（2023）05-093-06
作者:
周 钧a; 汪庭军b; 唐 珍a
（苏州市立医院北区 a. 检验科；b. 普外科，江苏苏州 215008）
Author(s):
ZHOU Juna;  WANG Tingjunb;  TANG Zhena
（a.Department of Clinical Laboratory; b. Department of General Surgery, North District of Suzhou Municipal Hospital, Jiangsu Suzhou 215008, China）
关键词:
甲状腺乳头状癌; 早期生长反应因子1; 早期生长反应因子2
分类号:
R736.1；R730.43
DOI:
10.3969/j.issn.1671-7414.2023.05.018
文献标志码:
A
摘要:
目的 探讨血清早期生长反应因子1（early growth response factor 1，EGR1）mRNA，早期生长反应因子2（earlygrowth response factor 2，EGR2）mRNA 表达水平在甲状腺乳头状癌（papillary thyroid carcinoma，PTC）患者早期诊断中的价值。方法 选择2019 年1 月～ 2022 年2 月在苏州市立医院确诊治疗的78 例PTC 患者（PTC 组）和46 例甲状腺良性肿瘤患者（良性肿瘤组）为研究对象，另以同期到该院体检的38 例健康者为对照组，收集整理所有PCT 患者的临床基本资料。采用实时荧光定量PCR 法检测各组血清EGR1 mRNA 和EGR2 mRNA 表达水平，比较PTC 患者、良性肿瘤患者和对照组血清EGR1 mRNA 和EGR2 mRNA 表达水平差异，分析PTC 患者血清EGR1 mRNA 和 EGR2 mRNA水平与患者临床病理特征的关系，采用Pearson 法分析PTC 患者血清EGR1 mRNA 和EGR2 mRNA 表达相关性，采用ROC 曲线分析血清EGR1 mRNA 和EGR2 mRNA 水平对PTC 患者早期诊断的价值。结果 对照组、良性肿瘤组和PTC组血清EGR1 mRNA（1.03±0.14，0.81±0.10，0.74±0.08），EGR2 mRNA（0.98±0.12，0.76±0.09，0.67±0.06）水平依次显著降低，差异具有统计学意义（F=103.402，166.508，均P<0.001）。肿瘤分期为Ⅲ～Ⅳ（0.71±0.13）、有淋巴结转移（0.69±0.12）、浸润程度超过包膜（0.67±0.17）的PTC 患者血清EGR1 mRNA 表达水平低于肿瘤分期为Ⅰ～Ⅱ、无淋巴结转移、浸润程度未浸润包膜的患者（0.78±0.15，0.77±0.16，0.79±0.18），差异有统计学意义（t=2.206，2.415，2.945，均P<0.05）；肿瘤分期为Ⅲ～Ⅳ（0.63±0.08）、有淋巴结转移（0.63±0.11）、浸润程度超过包膜（0.58±0.12）的PTC 患者血清EGR2 mRNA表达水平低于肿瘤分期为Ⅰ～Ⅱ、无淋巴结转移、浸润程度未浸润包膜的患者（0.71±0.12，0.70±0.14，0.73±0.16），差异有统计学意义（t=3.481，2.382，4.455，均P<0.05）；Pearson 相关性分析显示，PTC患者血清中EGR1 mRNA 与EGR2 mRNA 表达呈正相关（r=0.216，P<0.05）；血清EGR1 mRNA 和EGR2 mRNA 水平联合检测早期诊断PTC 的ROC 曲线下面积为0.829，敏感度、特异度分别为85.90%，73.91%。结论 PTC 患者血清EGR1 mRNA，EGR2 mRNA 水平下调，其水平变化与PTC 病情发展密切相关，二者联合检测对PTC 早期诊断具有重要意义。
Abstract:
Objective To investigate the value of serum early growth response factor 1(EGR1) mRNA and early growth response factor 2(EGR2) mRNA levels in the early diagnosis of papillary thyroid carcinoma (PTC). Methods Seventy-eight patients with PTC (PTC group) and forty-six patients with benign thyroid tumor (benign tumor group) diagnosed and treated in the North District of Suzhou Municipal Hospital from January 2019 to February 2022 were selected as the study objects, in addition, 38 healthy people who came to the North District of Suzhou Municipal Hospital for physical examination at the same time were taken as the control group, the basic clinical data of all PCT patients were collected and sorted out. The serum EGR1 mRNA and EGR2 mRNA levels in each group were detected by real-time fluorescent quantitative PCR, the differences in serum EGR1 mRNA and EGR2 mRNA expression levels were compared among PTC patients, benign tumor patients and control group, the relationship between serum EGR1 mRNA, EGR2 mRNA levels and clinicopathological characteristics of PTC patients was analyzed, Pearson method was applied to analyze the correlation between serum EGR1 mRNA and EGR2 mRNA expression in PTC patients, ROC curve was applied to analyze the value of serum EGR1 mRNA and EGR2 mRNA levels in early diagnosis of PTC patients. Results Serum EGR1 mRNA (1.03±0.14，0.81±0.10，0.74±0.08) and EGR2 mRNA (0.98±0.12，0.76±0.09， 0.67±0.06) levels in control group, benign tumor group and PTC group were significantly decreased successively，the differences were statistically significant (F=103.402, 166.508, all P<0.001). The expression level of serum EGR1 mRNA in PTC patients with tumor stage Ⅲ～Ⅳ（0.71±0.13）, lymph node metastasis （0.69±0.12）and invasion degree exceeding capsule （0.67±0.17）was lower than that in patients with tumor stage Ⅰ ～ Ⅱ , no lymph node metastasis and invasion degree not infiltrating capsule （0.78±0.15，0.77±0.16，0.79±0.18）, and the differences were statistically significant (t=2.206，2.415， 2.945，all P<0.05). The expression level of serum EGR2 mRNA in PTC patients with tumor stage Ⅲ ～ Ⅳ（0.63±0.08）, lymph node metastasis（0.63±0.11） and invasion degree exceeding capsule（0.58±0.12） was lower than that in patients with tumor stage Ⅰ ~ Ⅱ , no lymph node metastasis and invasion degree not invading capsule（0.71±0.12，0.70±0.14， 0.73±0.16）, the differences were statistically significant (t=3.481，2.382，4.455， all P<0.05). Pearson correlation analysis showed that there was a positive correlation between the expression of EGR1 mRNA and EGR2 mRNA in serum of PTC patients (r=0.216, P<0.05).The area under the ROC curve of the combined detection of serum EGR1 mRNA and EGR2 mRNA levels for early diagnosis of PTC was 0.829, and the sensitivity and specificity were 85.90% and 73.91%, respectively. Conclusion The serum EGR1 mRNA and EGR2 mRNA levels in patients with PTC were down-regulated, and their changes were closely related to the development of PTC. The combined detection of the two is of great significance for the early diagnosis of PTC.

参考文献/References:

[1] 刘美莲, 苏法铭, 李晓玲, 等．血管内皮生长因子和促血管生成素2 对甲状腺乳头状癌及颈部淋巴结转移的诊断价值[J]．实用医学杂志, 2021, 37（11）：1441-1444． LIU Meilian, SU Faming, LI Xiaoling, et al. Research on the predictive value of VEGF and Ang-2 in thyroid papillary carcinoma and its concomitant cervical lymph node metastasis [J]. Journal of Practical Medicine, 2021, 37(11): 1441-1444.
[2] COCA-PELAZ A, SHAH J P, HERNANDEZ-PRERA J C, et al. Papillary thyroid cancer-aggressive variants and impact on management: a narrative review[J].Advances in Therapy, 2020, 37(7): 3112-3128.
[3] KANG S Y, AHN H R, YOUN H J, et al. Prognosis of papillary thyroid carcinoma in relation to preoperative subclinical hypothyroidism[J]. Annals of the Royal College of Surgeons of England, 2021, 103(5): 367-373.
[4] 金婷, 曹含弘, 张斌, 等．2 型糖尿病患者EGR1，UACR 及CMI 指数与非酒精性脂肪性肝病的关系[J]. 海南医学, 2021, 32(23): 3003-3007. JIN Ting, CAO Hanhong, ZHANG Bin, et al. Association of EGR1,UACR and CMI with nonalcoholic fatty liver disease in type 2 diabetic patients[J]. Hainan Medical Journal, 2021, 32(23): 3003-3007.
[5] AI Kai, LI Xiaozhou, ZHANG Pan, et al. Genetic or siRNA inhibition of MBD2 attenuates the UUOand I/R-induced renal fibrosis via downregulation of EGR1[J]. Molecular Therapy Nucleic Acids, 2022, 28: 77-86.
[6] 李全营, 唐红娜, 秦长江, 等.STIP1 调控EGR1 表达并促进胃癌细胞DNA 损伤修复[J]. 消化肿瘤杂志( 电子版), 2022, 14(1): 14-20. LI Quanying, TANG Hongna, QIN Changjiang, et al. STIP1 regulates EGR1 expression and promotes DNA damage repair in gastric cancer cells [J]. Journal of Digestive Oncology(Electronic Version), 2022, 14(1): 14-20.
[7] 郭瑞霞, 陈玲燕, 张岩．EGR1 在乳腺癌组织中的表达及临床意义[J]．现代肿瘤医学, 2022, 30（10）：1767-1771． GUO Ruixia, CHEN Lingyan, ZHANG Yan. The expression and clinical significance of EGR1 in breast cancer[J]. Journal of Modern Oncology, 2022, 30(10): 1767-1771.
[8] 马俊福, 孟庆良, 苗喜云, 等．转录因子EGR2/EGR3 在类风湿关节炎寒证中的作用机制[J]．世界科学技术- 中医药现代化, 2021, 23（8）：2816-2822． MA Junfu, MENG Qingliang, MIAO Xiyun, et al. Mechanism of transcription factor EGR2/EGR3 in cold syndrome of rheumatoid arthritis[J]. World Science and Technology-Modernization of Traditional Chinese Medicine, 2021, 23(8): 2816-2822.
[9] GENG Xiang, SUN Yangyang, FU Jinjin, et al. MicroRNA-17-5p inhibits thyroid cancer progression by suppressing early growth response 2 (EGR2)[J].Bioengineered, 2021, 12(1): 2713-2722.
[10] CHEN Mi, FAN Li, ZHANG Simin, et al. LINC01939 inhibits the metastasis of gastric cancer by acting as a molecular sponge of miR-17-5p to regulate EGR2 expression[J]. Cell Death Dis, 2019, 10(2): 70.
[11] 王玲, 王健, 赵寅生, 等. 甲状腺乳头状癌患者血清促甲状腺激素水平和组织促甲状腺激素受体检测的临床应用价值[J]. 现代检验医学杂志, 2021, 36(1):61-64. WANG Ling, WANG Jian, ZHAO Yinsheng, et al. Clinical application value of serum thyrotropin level and tissue thyrotropin receptor detection in patients with thyroid papillary carcinoma[J]. Journal of Modern Laboratory Medicine, 2021, 36(1): 61-64.
[12] CARTWRIGHT S, FINGERET A. Contemporary evaluation and management of tall cell variant of papillary thyroid carcinoma[J]. Current Opinion in Endocrinology, Diabetes, and Obesity, 2020, 27(5): 351-357.
[13] 曹丽红, 朱玉海, 姜若愚．血清CD26 对于甲状腺乳头状癌的诊断价值及临床意义[J]．中国肿瘤临床,2020, 47(15): 788-791. CAO Lihong, ZHU Yuhai, JIANG Ruoyu. Diagnostic value and clinical significance of serum CD26 in papillary thyroid carcinoma[J]. Chinese Journal of Clinical Oncology, 2020, 47(15): 788-791.
[14] ZEMBSKA A, JAWIARCZYK-PRZYBY?OWSKA A, WOJTCZAK B, et al. MicroRNA expression in the progression and aggressiveness of papillary thyroid carcinoma[J]. Anticancer Research, 2019, 39(1): 33-40.
[15] 张哲, 商建峰, 王伟, 等．联合检测CK19, MC, TPO及CD56 在甲状腺乳头状癌病理诊断中的意义[J]．临床与实验病理学杂志, 2020, 36(5): 598-600. ZHANG Zhe, SHANG Jianfeng, WANG Wei, et al. The significance of combined detection of CK19,MC,TPO and CD56 in pathological diagnosis of thyroid papillary carcinoma[J]. Chinese Journal of Clinical and Experimental Pathology, 2020, 36(5): 598-600.
[16] 杜炜玮, 段铮, 胡斌．经皮RFA 治疗原发性肝癌的效果及对血清TGF-β1, EGR2 水平的影响[J]. 分子诊断与治疗杂志, 2022, 14(4): 635-638. DU Weiwei, DUAN Zheng, HU Bin. Effect of percutaneous RFA in the treatment of primary liver cancer and its influence on serum TGF-β1,EGR2 levels[J]. Journal of Molecular Diagnosis and Therapy, 2022, 14(4): 635-638.
[17] 曾伟兰, 汪艳．早期生长反应蛋白1 参与肝病发生主要病理机制研究进展[J]．中国药理学与毒理学杂志, 2020, 34（9）：702-712． ZENG Weilan, WANG Yan. Research progress in involvement of early growth response factor protein 1 in pathogenesis of chronic liver diseases[J]. Chinese Journal of Pharmacology and Toxicology, 2020, 34(9): 702-712.
[18] JUNG S N, OH C, CHANG J W, et al. EGR1/GADD45α activation by ROS of non-thermal plasma mediates cell death in thyroid carcinoma[J]. Cancers, 2021, 13(2): 351.
[19] LI Lechen, AMERI A H, WANG Simeng, et al. EGR1 regulates angiogenic and osteoclastogenic factors in prostate cancer and promotes metastasis[J]. Oncogene, 2019, 38(35): 6241-6255.
[20] GUO Hao, ZHANG Linlei. EGR1/2 inhibits papillary thyroid carcinoma cell growth by suppressing the expression of PTEN and BAX[J]. Biochemical Genetics, 2021, 59(6): 1544-1557.
[21] 郑炜, 马俊福．转录因子EGR2/EGR3 的生物学作用及与自身免疫性疾病的相关性[J]. 医学研究生学报, 2018, 31(5): 524-528. ZHENG Wei, MA Junfu. Study on EGR2/EGR3 and autoimmune diseases[J]. Journal of Medical Postgraduates, 2018, 31(5): 524-528.
[22] REGAN J L, SCHUMACHER D, STAUDTE S, et al. Identification of a neural development gene expression signature in colon cancer stem cells reveals a role for EGR2 in tumorigenesis[J]. iScience, 2022, 25(7): 104498.
[23] BUCHOU C, LAUD-DUVAL K, VAN DER ENT W, et al. Upregulation of the mevalonate pathway through EWSR1-FLI1/EGR2 regulatory axis confers ewing cells exquisite sensitivity to statins[J]. Cancers(Basel), 2022, 14(9): 2327.
[24] ZANG C S, HUANG H T, QIU J, et al. MiR-224-5p targets EGR2 to promote the development of papillary thyroid carcinoma[J]. European Review for Medical and Pharmacological Sciences, 2020, 24(9): 4890-4900.

相似文献/References:

[1]李桂荣,赵清侠a,宋 斌b,等.miR-221与miR-222在甲状腺乳头状癌组织中的表达及临床意义[J].现代检验医学杂志,2017,32(01):41.[doi:10.3969/j.issn.1671-7414.2017.01.012]
　LI Gui-rong,ZHAO Qing-xiaa,SONG Binb,et al.Expression of miR-221 and miR-222 in Papillary Thyroid Carcinoma Tissues and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2017,32(05):41.[doi:10.3969/j.issn.1671-7414.2017.01.012]
[2]孟凡萍,郝 坡,范 慧.甲状腺乳头状癌并发桥本氏甲状腺炎患者BRAF-V600E 基因表达及T 淋巴细胞亚群分析[J].现代检验医学杂志,2020,35(01):32.[doi:10.3969/j.issn.1671-7414.2020.01.009]
　MENG Fan-ping,HAO Po,FAN Hui.Expression of BRAF-V600E Gene and Analysis of Lymphocyte Subgroup in Thyroid Papillary Carcinoma Combined with Hashimoto's Thyroiditis[J].Journal of Modern Laboratory Medicine,2020,35(05):32.[doi:10.3969/j.issn.1671-7414.2020.01.009]
[3]王　玲,王　健,赵寅生,等.甲状腺乳头状癌患者血清促甲状腺激素水平和组织促甲状腺激素受体检测的临床应用价值[J].现代检验医学杂志,2021,36(01):61.[doi:10.3969/j.issn.1671-7414.2021.01.016]
　WANG Ling,WANG Jian,ZHAO Yin-sheng,et al.Clinical Application Value of Serum Thyrotropin Level and Tissue Thyrotropin Receptor Detection in Patients with Thyroid Papillary Carcinoma[J].Journal of Modern Laboratory Medicine,2021,36(05):61.[doi:10.3969/j.issn.1671-7414.2021.01.016]
[4]宋晓龙,宋 宇,魏 龙,等.血清TK1，TSH，TG，TGAb 检测联合TI RADS 分类在甲状腺乳头状癌早期筛查中的应用价值[J].现代检验医学杂志,2022,37(04):38.[doi:10.3969/j.issn.1671-7414.2022.04.008]
　SONG Xiao-long,SONG Yu,WEI Long,et al.Clinical Value of Serum TK1, TSH, TG and TGAb Detection Combined with TI-RADS Classification in Papillary Thyroid Carcinoma[J].Journal of Modern Laboratory Medicine,2022,37(05):38.[doi:10.3969/j.issn.1671-7414.2022.04.008]
[5]宋晓龙,魏 龙,秦晋铝,等.甲状腺乳头状癌患者术前血清TK1 表达水平联合甲状腺超声特征构建中央区淋巴结转移预测模型及验证[J].现代检验医学杂志,2023,38(01):1.[doi:10.3969/j.issn.1671-7414.2023.01.001]
　SONG Xiao-long,WEI Long,QIN Jin-lü,et al.Construction and Validation of Prediction Model of Central Lymph Node Metastasis in Patients with Papillary Thyroid Carcinoma Based on Preoperative Serum TK1 Expression Level and Thyroid Ultrasound Features[J].Journal of Modern Laboratory Medicine,2023,38(05):1.[doi:10.3969/j.issn.1671-7414.2023.01.001]
[6]刘 星,霍占江.甲状腺乳头状癌组织中galecti-3 与miR-375 水平表达意义及相关性研究[J].现代检验医学杂志,2023,38(01):49.[doi:10.3969/j.issn.1671-7414.2023.01.010]
　LIU Xing,HUO Zhan-jiang.Expression Significance and Correlation of galectin-3 and miR-375 in Papillary Thyroid Carcinoma Tissue[J].Journal of Modern Laboratory Medicine,2023,38(05):49.[doi:10.3969/j.issn.1671-7414.2023.01.010]
[7]那将超,狄长安.甲状腺乳头状癌患者术后血清MMIF 和IL-6 表达水平与甲状旁腺功能减退持续时间的相关性研究[J].现代检验医学杂志,2023,38(01):191.[doi:10.3969/j.issn.1671-7414.2023.01.036]
　NA Jiang-chao,DI Chang-an.Correlation between Postoperative Serum MMIF and IL-6 Expression Levels and Duration of Hypoparathyroidism in Patients with Papillary Thyroid Cancer[J].Journal of Modern Laboratory Medicine,2023,38(05):191.[doi:10.3969/j.issn.1671-7414.2023.01.036]
[8]薛思军a,涂霁韬b.甲状腺乳头状癌组织中miR-137 水平表达及相关实验研究[J].现代检验医学杂志,2023,38(04):121.[doi:10.3969/j.issn.1671-7414.2023.04.022]
　XUE Sijuna,TU Jitaob.Expression of miR-137 in Papillary Thyroid Carcinoma Tissue and Its Related Experimental Study[J].Journal of Modern Laboratory Medicine,2023,38(05):121.[doi:10.3969/j.issn.1671-7414.2023.04.022]

备注/Memo

备注/Memo:
基金项目： 2015 年度南京医科大学科技发展基金项目（2015NJMU129）：钙剂对继发性甲状旁腺次全切除术后的血透患者血清BALP 的相关研究。
作者简介：周钧（1983-），男，本科，副主任技师，研究方向：临床生物化学和免疫学，E-mail：vruzhc@163.com。
通讯作者：唐珍（1986-），女，本科，副主任技师，研究方向 : 临床免疫和化学发光。
更新日期/Last Update: 2023-09-15